Case report
The patient, a 72-year-old Caucasian male presented at our clinic with
complaints of poor motivation, memory problems , insomnia, restlessness,
tremor and difficulty with walking. At the time his medications included
L-dopa, amantadine, memantine and paliperidone. He was a widower and
lived alone. He did not endorse any prior history of neurological
problems, strokes, psychiatric disorders or medical ailments. He did
have a history of alcohol abuse, but stopped drinking completely
approximately one year prior to his visit, at the recommendation of his
primary care physician.
He initially presented to his primary care physician with heightened
concerns about his difficulties with his memory. He also endorsed poor
motivation and inability to “carry on with life”. He lived alone,
having lost his wife 6 years earlier. He did not have much contact with
his extended family, and no longer enjoyed leisure activities including
his daily game of golf. A Mini-Mental Status exam administered at the
time indicated mild to moderate cognitive impairment. He was given a
trial of sertraline 25 mg daily for 2 months with no improvement. This
was subsequently increased to 50 mg daily for another month, at which he
time he reported further deterioration in his memory and increased
restlessness. Paliperidone 3 mg at night along with donepezil 10 mg
daily was then added to his medication regimen. At follow-up he was
found to have increased problems with recent and remote memory,
motivation, with anhedonia, poor sleep, tremor, mild cogwheel rigidity
and a festinant shuffling gait. Lab testing done on the patient
including a CBC, CMP, thyroid profile, liver profile, serum folate, B12,
vitamin D 3, RPR levels and urine toxicology were all normal. The
patient was then referred by his primary care physician to a neurologist
for further evaluation and treatment. He was subsequently diagnosed with
Parkinson’s disease and placed on L-dopa 300 mg daily increased over 2
months to 600 mg daily. No improvement was noted, at which time
donepezil was discontinued. Amantadine 200 mg daily was added to his
medication regimen, along with memantine 20 mg daily. Surprisingly he
was continued on paliperidone increased to 6 mg daily. He was noted to
be markedly confused, with further deterioration in his memory, mood,
motivation and sleep. Further testing done included repeat liver
functions and Serum copper/ceruloplasmin levels which were normal. An
MRI of the brain showed mild generalized atrophy, and an EEG which was
normal.
He opted to seek a second opinion on the recommendation of his primary
care physician, and presented to our clinic with significant complaints
of confusion, memory impairment, loss of interest in life, restlessness,
difficulties with performing daily activities of living, insomnia and
problems with his gait . Upon first examination he was noted to be
mildly sedated, a little confused with a monotonous voice. He was fairly
well oriented but with significant disturbance in immediate, recent and
remote memory. He showed little interest in cognitive testing and a
Mini-Mental Status exam indicated 16 out of 30 points. His affect was
flat and expressionless and his mood was apathetic and depressed and
congruent with his affect. His thought processes were somewhat
disorganized and tangential. He was not delusional. He did not exhibit
any hallucinations. His insight and judgment appear to be compromised.
Neurological examination revealed no clear deficits in his cranial
nerves II through XII. His muscle tone short symmetrical mild cogwheel
rigidity. His reflexes were bilaterally depressed. Babinski was
negative.
He exhibited a mild pin-rolling tremor. He walked with slow shuffling
steps and had some difficulty with his balance. Romberg test was
negative and there was no evidence of cerebellar dysfunction.
With his full informed consent his medications were tapered off and
discontinued over 2 weeks. After careful deliberation regarding a robust
SSRI retrial vs Selegiline, he opted for treatment with Selegiline. He
was placed on a tyramine free diet, and advised to maintain complete
sobriety with his use of alcohol, which he had stopped completely
approximately 6 months prior to his visit with us. He was then placed on
selegiline 20 mg daily and followed up in 2 weeks with no significant
improvement in his cognition or mood. It was noted that his affect was
more appropriate, and his rigidity and tremor had decreased. Selegiline
was increased to 40 mg daily and further follow up visit arranged in 2
weeks with no significant changes. Subsequently he was placed on
selegiline at 60 mg daily and seen in another 2 weeks. At that time he
was noted to be quite alert and active and cheerful. His cognitive
functioning seemed to have returned to normal with a score of 28 out of
30 on the Mini-Mental status examination.
Cogwheeling rigidity, tremor and shuffling gait had disappeared. He was
sleeping much better and showed good motivation. He continued to
maintain sobriety, was able to perform all activities of daily living,
and develop a more social lifestyle including returning to his leisure
activities, especially golf.
In follow up at 1 month intervals for the next 1 year he continued to be
stable on selegiline, reduced to 40 mg daily with complete sobriety from
alcohol and no other medications.